Fibrocell Science, Inc. Board of Directors Accepts Resignation of Chief Operating Officer and Chief Financial Officer Declan Daly

Published: Jul 01, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Declan Daly, Chief Operating Officer and Chief Financial Officer, will resign to reside in Ireland full time. Fibrocell has initiated an executive search to replace Daly with a Chief Financial Officer who will be based in Fibrocell’s Exton, PA facility. Daly will remain with the Company through November 2013 to assure a smooth transition to a successor.

Help employers find you! Check out all the jobs and post your resume.

Back to news